Annovis Bio (NYSE: ANVS)
Annovis Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Annovis Bio Company Info
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aims to treat neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
News & Analysis
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.
Got $2,500? Check Out These 3 Alzheimer's Therapy Stocks
Treating Alzheimer's is extremely difficult, but these innovative companies are taking a stab at it.
This Biotech Stock Is Up 884% In 2021, But It Could Go Even Higher
With updates from clinical trials expected as soon as this month, anything is possible.
3 Biotech Stocks That Jumped Higher Last Week
Find out what pushed them up to see if the good times can keep rolling.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.